306 related articles for article (PubMed ID: 18410960)
21. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.
Menzies-Gow A; Flood-Page P; Sehmi R; Burman J; Hamid Q; Robinson DS; Kay AB; Denburg J
J Allergy Clin Immunol; 2003 Apr; 111(4):714-9. PubMed ID: 12704348
[TBL] [Abstract][Full Text] [Related]
22. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
23. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice.
Rothenberg ME; Ownbey R; Mehlhop PD; Loiselle PM; van de Rijn M; Bonventre JV; Oettgen HC; Leder P; Luster AD
Mol Med; 1996 May; 2(3):334-48. PubMed ID: 8784786
[TBL] [Abstract][Full Text] [Related]
24. Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis.
Bullock JZ; Villanueva JM; Blanchard C; Filipovich AH; Putnam PE; Collins MH; Risma KA; Akers RM; Kirby CL; Buckmeier BK; Assa'ad AH; Hogan SP; Rothenberg ME
J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):22-31. PubMed ID: 17592361
[TBL] [Abstract][Full Text] [Related]
25. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
26. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders.
Foroughi S; Foster B; Kim N; Bernardino LB; Scott LM; Hamilton RG; Metcalfe DD; Mannon PJ; Prussin C
J Allergy Clin Immunol; 2007 Sep; 120(3):594-601. PubMed ID: 17765756
[TBL] [Abstract][Full Text] [Related]
27. Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies.
Legrand F; Cao Y; Wechsler JB; Zhu X; Zimmermann N; Rampertaap S; Monsale J; Romito K; Youngblood BA; Brock EC; Makiya MA; Tomasevic N; Bebbington C; Maric I; Metcalfe DD; Bochner BS; Klion AD
J Allergy Clin Immunol; 2019 Jun; 143(6):2227-2237.e10. PubMed ID: 30543818
[TBL] [Abstract][Full Text] [Related]
28. Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis.
Conus S; Straumann A; Bettler E; Simon HU
J Allergy Clin Immunol; 2010 Jul; 126(1):175-7. PubMed ID: 20542323
[No Abstract] [Full Text] [Related]
29. Current update on eosinophilic lung diseases and anti-IL-5 treatment.
Samitas K; RĂ¥dinger M; Bossios A
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):189-205. PubMed ID: 21824072
[TBL] [Abstract][Full Text] [Related]
30. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
31. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
32. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.
Park CW; Lee BH; Han HJ; Lee CH; Ahn HK
Br J Dermatol; 2005 Jun; 152(6):1173-81. PubMed ID: 15948978
[TBL] [Abstract][Full Text] [Related]
33. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression.
Gregory B; Kirchem A; Phipps S; Gevaert P; Pridgeon C; Rankin SM; Robinson DS
J Immunol; 2003 Jun; 170(11):5359-66. PubMed ID: 12759409
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
Corren J
Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
[TBL] [Abstract][Full Text] [Related]
35. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
36. The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders.
Legrand F; Tomasevic N; Simakova O; Lee CC; Wang Z; Raffeld M; Makiya MA; Palath V; Leung J; Baer M; Yarranton G; Maric I; Bebbington C; Klion AD
J Allergy Clin Immunol; 2014 May; 133(5):1439-47, 1447.e1-8. PubMed ID: 24530099
[TBL] [Abstract][Full Text] [Related]
37. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab.
Pouliquen IJ; Kornmann O; Barton SV; Price JA; Ortega HG
Int J Clin Pharmacol Ther; 2015 Dec; 53(12):1015-27. PubMed ID: 26445140
[TBL] [Abstract][Full Text] [Related]
39. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
40. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]